Management of COPD Updates and Evidence
|
|
- Helen Walters
- 5 years ago
- Views:
Transcription
1 Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD
2 Disclosures All presenters of this activity have no financial relationships relevant to this activity
3 Objectives 1. Describe the updated recommendations in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD 2. Compare and contrast therapies for management of COPD based on evidence from recent clinical trials 3. Develop a management plan for COPD using 2017 GOLD guidelines
4 Pre-Test 1. Which inhaled medication is no longer a preferred agent in the management of COPD? 2. Which inhaled medication(s) is now emphasized/ preferred in all ABCD severity groups? 3. What class of medications was added to step-up therapy for an exacerbation in a group D patient? 4. What are goals of treatment for improving inhaler technique? 5. Based on results from the FLAME study, which combination of inhaled medications lengthened time between exacerbations? 6. What did the results of the WISDOM study show in relation to withdrawing ICS from patients on triple therapy? 7. What population(s) was shown to benefit most from adding roflumilast to maintenance therapy? 8. What should be assessed in regard to medication use in all patients prior to escalating therapy in COPD?
5 COPD Death Rates in the United States Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):
6 Revisions to the GOLD Guidelines Updated the definition of COPD Separated GOLD category from COPD severity group Added long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) to mild COPD patients Removed inhaled corticosteroids (ICS) as preferred agents in the group C and D Added azithromycin and erythromycin as alternative agents Emphasized inhaler technique teaching Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
7 Definition of COPD Common, preventable, and treatable pulmonary disease Persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities Usually caused by interaction of significant exposure to noxious particles gases and specific host factors Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
8 Question 1: Which of the following GOLD grades and severity groups are appropriate for a 65- year old with COPD Assessment Test (CAT) score of 28 today, not COPD exacerbations in the past year and forced expiratory volume in 1 second (FEV1) of 29% of the predicted value 1 month ago? A. GOLD grade 4, group B B. GOLD grade 4, group D C. GOLD grade 1, group A D. GOLD grade 1, group C
9 Severity of Airflow Limitation - GOLD Grades Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
10 2016 GOLD Guidelines Severity Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
11 2017 GOLD Guidelines Severity Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
12 COPD Assessment based on GOLD Use Spirometry to diagnose COPD and assess airflow limitation (GOLD grade) 2. Use CAT or mmrc to assess COPD symptom severity 3. Determine exacerbation risk: a. Number of COPD exacerbations in past 12 months b. Number of COPD-related hospitalizations in the past year
13 Question 2: Which of the following types of medications are currently recommended for a 45-year old with one COPD-related hospitalization in the past year, a CAT score of 28 and a FEV1 49% and the predicted value with no airway reversibility who is using an albuterol metered-dose inhaler (MDI) 90 mcg 2 puffs 3-4 times/ day for COPD symptoms? A. Tiotropium/ Olodaterol B. Budesonide/ Formoterol C. Fluticasone/ Umeclidinium/Vilanterol D. Ipratropium/ Albuterol
14 2016 GOLD: Initial Medications Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
15 2017 GOLD: Initial Medications Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
16 Question 3: Which of the following step-up options is recommended for a 75-year old woman with GOLD grade 4, group D COPD currently taking ICS/LABA and a LAMA? She is adherent to her inhalers and is able to use them correctly. She is on 2L of oxygen/ 24 hours. She continues to have a CAT score of 30 and a COPD exacerbation every other month. Despite quitting smoking 1 year ago, she is losing weight and complains of feeling depressed. A. Azithromycin B. Roflumilast C. Theophylline D. Prednisone
17 Step-up / Alternative Medications 2016 LAMA and/or LABA and/or ICS combinations SAMA + SABA Theophylline Roflumilast + LAMA Roflumilast + LABA ICS + LABA + roflumilast 2017 LAMA and/or LABA combination LABA + ICS LAMA + LABA + ICS Step-up: Roflumilast Azithromycin Erythromycin Other: ICS withdrawal? Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
18 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
19 Azithromycin and Erythromycin Decreased exacerbations when used for 6-12 months No significant decrease in hospitalizations or overall mortality Increased side-effects Unknowns: Optimal dosing Duration of therapy (no data past 12 months) Subpopulations with the most benefit Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS ONE. 2015;10(3):e
20 ICS Withdrawal Mixed data on if w/d increases lung function and/or decreases exacerbations Background use of LAMA or LABA may minimize effect Modest decrease in FEV1 (~ 40mL) Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14): Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390-8.
21 Triple Inhaled Therapy LABA + LAMA + ICS = triple inhaled therapy Fluticasone furoate + umeclidinium + vilanterol 100 mcg/62.5 mcg/ 25 mcg (Trelegy Ellipta ) daily -- approved September 2017 Add LAMA to existing LABA/ICS regimen improves lung function and patient reported exacerbations Single study found no benefit of adding ICS to LABA/LAMA combination More evidence needed if triple inhaled therapy is more beneficial than LABA/LAMA alone Brusselle G, Price D, Gruffydd-jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10: Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):
22 Question 4: A 55-year old with COPD returns to clinic with questions about the proper use of his Respimat inhaler. Which of the following techniques is correct for the use of this inhaler? A. Priming the inhaler before the first use B. Opening the cap and then twisting the base C. Placing the mouthpiece 2 finger spaces away from the mouth D. Inhaling use a quick and steady breath
23 Critical Errors with Inhalers Van der palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079.
24 Question 5: A COPD patient reports a history of intolerance to propellants in inhalers. Which of the following inhalation delivery systems uses a propellant? A. Metered-dose inhaler B. Dry powder inhaler C. Jet nebulizer D. Propellants are no longer used inhalation devices
25 Goals of Treatment with Inhaler Emphasis Reduce risk Reduce symptoms Personalized Inhaler improvement: Facilitate drug deliver Reduce frequency Minimize number of inhalers Still the same drug classes. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD
26 Procalcitonin Procalcitonin guided antibiotics associated with decreased antibiotic exposure without affecting clinical outcomes (Evidence: Low- Moderate) Specific for bacterial infections Rule out patients who may not benefit from antibiotics during exacerbations Christ-crain M, Jaccard-stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409): Schuetz P, Christ-crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):
27 Recently Published Evidence FULFIL FLAME WISDOM RE 2 SPOND Tie-COPD
28 Question 6: How are COPD exacerbations classified per GOLD guidelines? Mild Moderate Severe True or False: FEV1 is a good marker to determine likelihood of exacerbation risk
29 Question 6: How are COPD exacerbations classified per GOLD guidelines? Mild - can be treated with short acting bronchodilators (SABD) Moderate - treated with SABD + antibiotics + PO corticosteroids Severe - requires hospitalization or ER visit True or False: FEV 1 is a good marker to determine likelihood of exacerbation risk - False
30 FULFIL Study Study comparing once a day triple agent therapy in a single inhaler with two agent twice a day therapy in a single inhaler for those at high risk of exacerbations 24 week randomized control trial double blind and double dummy Fluticasone 100 mcg + Umeclidinium 62.5 mcg + Vilanterol 25 mcg (ICS + LAMA + LABA) once daily VS Budesonide 400 mcg + Formoterol 12 mcg (ICS + LABA) twice daily Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):
31 FULFIL Study Population n = year old males (74%) Current or past average 39 pack year smoking history Average FEV 1 = 49% predicted (~ GOLD 3) About 65% experienced > 1 moderate or severe exacerbation in the previous year Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):
32 FULFIL Design & Results Outcomes ITT LAMA + LABA + ICS LABA + ICS P value Primary Mean change in FEV 1 from baseline Mean change in SGRQ from baseline ml - 29 ml < units units <0.001 Secondary Rate of mild, moderate & severe exacerbations Addition of LAMA to LABA + ICS therapy reduced rate by 35% ADE Pneumonia 20/911 (2.2%) 7/899 (0.8%) Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):
33 Mean Change in FEV1 from Baseline Baseline Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):
34 FULFIL Study Discussion Contributes to current evidence that has already shown adding LAMA to LABA + ICS results in improvement in lung function and QoL This product likely provides benefit in regards to patient adherence Funded by GSK, makers of Trelegy Ellipta TM inhaler Did not report pre-enrollment COPD maintenance regimens Improvement of FEV 1 has questionable clinical significance Frith PA, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomized controlled trial. Thorax 2015; 70(6): Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):
35 FLAME Study A study comparing exacerbation rate for dual long acting bronchodilator therapy with the standard of care (LABA + ICS) for those with severe COPD 52 week RCT double blind, double dummy, non-inferiority trial (HR margin 15%) Indacaterol 110 mcg + Glycopyrronium 50 mcg (LAMA + LABA) once daily VS Salmeterol 50 mcg + Fluticasone 500 mcg (LABA + ICS) twice daily Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;
36 FLAME Study Population n = 3362 ~ 65 year old males (76%) Generally diagnosed COPD for 7.3 yrs and Group D at time of study (74.8%) Average FEV 1 = 44.1% predicted Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;
37 FLAME Design & Methods Outcomes ITT LAMA + LABA LABA + ICS Rate ratio Primary Annual rate of any exacerbation (11% lower) p = LAMA + LABA was non-inferior to LABA + ICS for decreasing annual rate of any COPD exacerbation Secondary Time to 1st exacerbation of any severity Annual rate mod/severe exacerbation Time to 1st mod/severe exacerbation 71 days 51 days 0.84 (16% lower) p < % 0.83 (17% lower) p < days 87 days 0.78 (22% lower) p < Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;
38 FLAME Results Favors LABA + LAMA Favors LABA + ICS Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;
39 FLAME Discussion LAMA + LABA is not inferior to LABA + ICS in reducing rate of exacerbations Demonstrated that LAMA + LABA combination also lengthened time between exacerbations compared to the standard of therapy Study was not powered to assess impact of the two treatment groups on severe exacerbations Some of the LABA + LAMA group recieved ICS prior to enrollment
40 Available LABA + LAMA agents Brand Generic Dose FDA approval Bevespi TM Aerosphere MDI Glycopyrrolate + formoterol 2 puffs BID 2016 Utibron TM Neohaler Glycopyrrolate + indacaterol 1 capsule BID 2015 Stioltio TM Respimat MDI Tiotropium + olodaterol 2 puffs QD 2015 Anoro TM Ellipta DPI Umeclidinium + vilanterol 1 puff QD 2013 Duaklir TM Genuair DPI Aclidinium + formoterol 1 puff BID Seeking 2018
41 Question 7: A 62 yo woman with GOLD stage 2 and is being discharged today for her 3rd COPD exacerbation this year. The doctor was planning to continue her home Symbicort TM and Spiriva TM. PMH: CAD, T2DM, osteoporosis and reports variable adherence to inhalers What medication change (if any) would you recommend to optimize therapy? A. Change to Umeclidinium + vilanterol (Anoro Ellipta TM ) B. Discontinue Spiriva TM C. No changes, she is on optimum therapy D. Add Roflumilast
42 WISDOM Study Assess the impact of ICS withdrawal from triple therapy on COPD exacerbations 52 week double blind, parallel group non-inferiority study (hazard ratio margin 1.2) Tiotropium 18 mcg QD + Salmeterol 50 mcg BID + Fluticasone 500 mcg BID Triple Therapy x 6 weeks Continue triple therapy VS Withdraw Fluticasone 500 mcg BID in 3 steps over 12 weeks Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
43 WISDOM Study Population n = year old males (82.5%) Mainly caucasian Average COPD diagnosis for 7.87 years with FEV 1 < 50% (99.3%) Average FEV 1 (34.2% predicted) Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
44 WISDOM Results Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
45 WISDOM Results Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
46 WISDOM Results Primary endpoint Withdrawing ICS from triple therapy was not inferior to continuing therapy when evaluating time to first moderate to severe exacerbation Hazard ratio 1.06 (CI: ) Secondary endpoints Time to first severe exacerbation hazard ratio 1.2 At 18 weeks the trough FEV 1 was greater (38 ml) than those on triple therapy No significant differences were noted for dyspnea or minor health status Safety Incidence of pneumonia was similar between the groups Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
47 WISDOM Discussion Shows ICS may not be needed in all COPD patients and can be safely withdrawn without resulting in an increase in exacerbations Only specific populations likely continue to confer benefit from ICS ie: Asthma - COPD Overlap Syndrome (ACOS) Generalizability was limited since population was mostly male and Caucasian High dose ICS used (500 mcg BID) Magnussen H, Disse B, Rodriguez-roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):
48 RE 2 SPOND Study The REACT study showed roflumilast is an effective add-on agent to decrease moderate or severe exacerbations and hospitalizations. RE 2 SPOND builds on REACT to determine which subgroup benefits most from roflumilast 52 week, multicenter, phase 4, RCT, double blind, placebo controlled Any ICS + LABA + LAMA for > 3 months Roflumilast 500 mcg once daily x 52 weeks VS Placebo x 52 weeks Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016;194(5):
49 RE 2 SPOND Population n = % used ICS + LABA and remaining also had LAMA 64 year old males (85%) Mostly caucasian (80%) ~ 2.4 exacerbations/hospitalizations in the past year FEV 1 = 33% predicted ~ 52.5 pack year smoking history Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016;194(5):
50 RE 2 SPOND Design and Results Outcomes Roflumilast Placebo RR (p-value) Primary Annual mod/severe exacerbation rate p = Did not achieve primary endpoint but shows trend that favors roflumilast Secondary Mean time to first exacerbation 319 days 286 days 0.9 p =0.323 Subgroup analysis Annual mod/severe exacerbation rate for those with hx >3 exacerbations/yr Annual mod/severe exacerbation rate for those with > 1 severe exacerbations/yr p = p = 0.01 Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med. 2016;194(5):
51 RE 2 SPOND Discussion Those with > 3 exacerbations a year and those with > 1 severe exacerbation in a year are the two populations that are most likely to benefit from roflumilast Limited ICS doses used in the study Maximum dose: fluticasone 250 mcg/salmeterol 50 mcg 1 BID Baseline population potentially were not on optimal therapy 47% were on concurrent LAMA (expected 60%)
52 Tie-COPD Study Study to evaluating use of long term LAMA in mild to moderate COPD patients who have minimal symptoms 2 year, multicenter, RCT, double blinded, phase 4 trial Tiotropium 18 mcg (LAMA) once daily VS Placebo Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(10):
53 Tie-COPD Population n = 841 Study subjects recruited from mainland China 64 year old males (85%) GOLD stage 1-2 ~ 52.5 pack year smoking history FEV 1 = 78% predicted Mean CAT score 7.1 Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(10):
54 Tie-COPD Design & Results Outcomes LAMA Placebo P value Primary Secondary Mean change in FEV 1 from baseline before SABD Mean change in FEV 1 from baseline after SABD Number of any exacerbation or hospitalization per pt/yr Number of moderate/severe exacerbation per pt/yr 38 ml 53 ml ml 51 ml < <0.001 Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(10):
55 Tie-COPD Discussion Roughly 70% of those with COPD have mild or minimal symptoms and the majority do not receive maintenance treatment Provides evidence supporting benefit of early initiation of LABA Initiation of LAMA showed slower decline in FEV 1 for those very early in the disease progression (GOLD 1 and 2) Generalizability of the study is limited given that the majority of the study population were Chinese Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(10): Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:
56 Post-Test 1. Which inhaled medication is no longer a preferred agent in the management of COPD? 2. Which inhaled medication(s) is now emphasized/ preferred in all ABCD severity groups? 3. What class of medications was added to step-up therapy for an exacerbation in a group D patient? 4. What are goals of treatment for improving inhaler technique? 5. Based on results from the FLAME study, which combination of inhaled medications lengthened time between exacerbations? 6. What did the results of the WISDOM study show in relation to withdrawing ICS from patients on triple therapy? 7. What population(s) was shown to benefit most from adding roflumilast to maintenance therapy? 8. What should be assessed in regard to medication use in all patients prior to escalating therapy in COPD?
57 Clinical Pearls Select appropriate inhaler device based on patient inspiratory flow rate Deterioration of inhaler technique over time, review administration technique with patients Dual bronchodilator (LABA + LAMA) is a the new strategy for managing COPD ICS therapy reserved for those at highest risk for exacerbations Roflumilast added to ICS + LABA ( +/- LAMA) therapy can reduce the rate of moderate or severe exacerbations
58 Questions?
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationNEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE *Caroline Charles Scilink Medical Writing *Correspondence to scilink.mw@gmail.com Disclosure: Medical writing assistance
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationPreventing clinically important deterioration with single-inhaler triple therapy in COPD
ORIGINAL ARTICLE COPD Preventing clinically important deterioration with single-inhaler triple therapy in COPD Ian Naya 1, Chris Compton 1, Afisi S. Ismaila 2,3, Ruby Birk 4, Noushin Brealey 4, Maggie
More informationBalanced information for better care. Helping patients with COPD breathe easier
Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationJournal of the COPD Foundation. Impact of the IMPACT Trial Ron Balkissoon, MD, MSc, DIH, FRCPC 1. Chronic Obstructive Pulmonary Diseases: Journal Club
221 Journal Club: The IMPACT Trial Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Impact of the IMPACT Trial Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: Global
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationNew Medicines Committee Briefing July Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD
Ultibro is to be reviewed for use within: New Medicines Committee Briefing July 2017 Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD Summary: Primary
More informationA Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD
A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationNEWER BRONCHODILATORS. Dr R Lakshmi Narasimhan SR Pulmonary Medicine
NEWER BRONCHODILATORS Dr R Lakshmi Narasimhan SR Pulmonary Medicine Topics to be covered Ultra LABA (+/-ICS) Newer LAMA LAMA + LABA Novel Bronchodilators Why the need for newer BD? OD dosing convenient
More informationRole of Long-Acting Muscarinic Antagonist/Long-Acting β 2 -Agonist Therapy in Chronic Obstructive Pulmonary Disease
705149AOPXXX10.1177/1060028017705149Annals of PharmacotherapyPetite review-article2017 Review Article Role of Long-Acting Muscarinic Antagonist/Long-Acting β 2 -Agonist Therapy in Chronic Obstructive Pulmonary
More informationNuovi farmaci in sviluppo per la BPCO
PNEUMOLOGIA 2018 MILANO, 14 16 GIUGNO 2018 CENTRO CONGRESSI PALAZZO DELLE STELLINE Nuovi farmaci in sviluppo per la BPCO Leonardo M. Fabbri, MD, FERS Professor of Respiratory and Internal Medicine, University
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationDebating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2
Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationFDCs for CO PD: From Famine to a Feast of Therapeutic Choices
FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for
More informationClass Update: Asthma / COPD Medications
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More information